Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11894-015-0444-2 http://scihub22266oqcxt.onion/10.1007/s11894-015-0444-2 C4451973!4451973!26031830     free     free     free       Curr+Gastroenterol+Rep 2015 ; 17 (6): ä Nephropedia Template TP {{tp|p=26031830|t=2015. Next-Generation Therapeutics for IBD |pdf=|usr=}}{{26031830}} gab.com Text Next-Generation Therapeutics for IBD JO: Curr Gastroenterol Rep http://www.kidney.de/pget.php?&tw=1&pmid=26031830 #FOAvip Various novel drugs have recently been evaluated in clinical trials showing promising effects in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-?4?7) and etrolizumab (anti-rhuMAb ?7), and the Janus kinase (JAK) inhibitor tofacitinib. Moreover, we will discuss efficacy and safety data of golimumab (a new subcutaneous anti-tumor necrosis factor (TNF) antibody), Avaxia (an orally delivered anti-TNF antibody), and Budesonide MMX; all have been developed for the treatment of ulcerative colitis. Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn?s disease patients. Twit Text FOAVip Next-Generation Therapeutics for IBD ????Curr Gastroenterol Rep http://www.kidney.de/pget.php?&tw=1&pmid=26031830 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26031830 #FOAvip English Wikipedia <ref>{{Cite pmid|26031830}}</ref> Next-Generation Therapeutics for IBD #MMPMID26031830 Löwenberg M; D?Haens G Curr Gastroenterol Rep 2015[]; 17 (6): ä PMID26031830show ga Various novel drugs have recently been evaluated in clinical trials showing promising effects in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-?4?7) and etrolizumab (anti-rhuMAb ?7), and the Janus kinase (JAK) inhibitor tofacitinib. Moreover, we will discuss efficacy and safety data of golimumab (a new subcutaneous anti-tumor necrosis factor (TNF) antibody), Avaxia (an orally delivered anti-TNF antibody), and Budesonide MMX; all have been developed for the treatment of ulcerative colitis. Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn?s disease patients. äNext-Generation Therapeutics for IBD (epmc).pdf DeepDyve Pubget Overpricing